[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

888-662-6728 (U.S. Only)

Email address

global-roche-genentech-trials@gene.com

Condition

Cervical Cancer,Clear Cell RCC,Urothelial Carcinoma,Esophageal Cancer,Gastric Cancer,HCC,HNSCC,Locally Advanced or Metastatic Solid Tumors,Melanoma,NSCLC,TNBC

Treatment type

Interventional

Investigational product

Atezolizumab

Phase

Phase 1

Sponsor

Genentech, Inc.

ClinicalTrials.gov identifier

NCT05581004

Study number

GO43860

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Life expectancy at least 12 weeks
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  3. Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
  4. Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
  5. Tumor Specimen availability
Exclusion criteria

  1. Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment
  2. Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
  3. Active hepatitis B or C or tuberculosis
  4. Positive test for human immunodeficiency virus (HIV) infection
  5. Acute or chronic active Epstein-Barr virus (EBV) infection at screening
  6. Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion
  7. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  8. Active or history of autoimmune disease
  9. Prior allogeneic stem cell or organ transplantation

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site